TEVA PHARMACEUTICAL-SP ADR (TEVA)
US8816242098 - ADR
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 3.23B | 2.80B | 2.17B | 2.18B | 1.98B | |||
| Marketable Securities | N/A | N/A | N/A | N/A | N/A | |||
| Receivables | 3.41B | 3.70B | 4.53B | 4.58B | 5.68B | |||
| Inventories | 4.02B | 3.83B | 3.82B | 4.40B | 4.42B | |||
| Other Current Assets | 1.83B | 1.72B | 2.06B | 1.84B | 1.39B | |||
| Total Current Assets | 12.49B | 12.05B | 12.57B | 13.01B | 13.46B | |||
| Non-Current Assets | ||||||||
| PPE Net | 6.15B | 6.16B | 6.48B | 6.86B | 6.95B | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Goodwill | 17.18B | 17.63B | 20.04B | 20.62B | 24.85B | |||
| Intangibles | 5.39B | 6.27B | 7.47B | 8.92B | 11.23B | |||
| Other Non-Current Assets | 2.28B | 1.90B | 1.11B | 1.23B | 978.00M | |||
| Total Non-Current Assets | 30.99B | 31.96B | 35.09B | 37.63B | 44.01B | |||
| TOTAL ASSETS | 43.48B | 44.01B | 47.67B | 50.64B | 57.47B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 23.00M | 23.00M | 23.00M | 514.00M | 514.00M | |||
| Current Portion Of LT Debt. | 1.65B | 2.09B | 1.40B | 2.67B | 1.83B | |||
| Accrued Expenses | 3.48B | 2.81B | 2.88B | 2.58B | 2.68B | |||
| Accounts Payable | 2.60B | 1.89B | 1.69B | 1.76B | 1.72B | |||
| Other Current Liabilities | 4.49B | 4.66B | 5.04B | 5.64B | 6.93B | |||
| Total Current Liabilities | 12.25B | 11.47B | 11.03B | 13.16B | 13.67B | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 18.16B | 19.10B | 21.62B | 22.73B | 24.56B | |||
| Deferred Taxes/Income | 606.00M | 548.00M | 784.00M | 964.00M | 1.10B | |||
| Other Non-Current Liabilities | 4.34B | 4.29B | 2.99B | 2.72B | 3.08B | |||
| Total Non-Current Liabilities | 23.73B | 24.74B | 26.36B | 27.45B | 29.82B | |||
| TOTAL LIABILITIES | 35.97B | 36.21B | 37.39B | 40.61B | 43.50B | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -13.53B | -12.97B | -10.53B | -10.95B | -6.96B | |||
| Additional Paid In Capital | 27.81B | 27.69B | 27.56B | 27.44B | 27.31B | |||
| Minority Interest | 676.00M | 847.00M | 927.00M | 1.14B | 1.09B | |||
| Common Shares | 57.00M | 57.00M | 57.00M | 57.00M | 56.00M | |||
| Treasury Stock | -4.13B | -4.13B | -4.13B | -4.13B | -4.13B | |||
| Other Shareholders' Equity | -2.70B | -2.84B | -2.68B | -2.40B | -2.31B | |||
| Shares Outstanding | 1.13B | 1.13B | 1.12B | 1.11B | 1.11B | |||
| Tangible Book Value per Share | -13.43 | -14.36 | -15.61 | -17.80 | -20.24 | |||
| Total Shareholders' Equity | 7.51B | 7.80B | 10.28B | 10.03B | 13.97B | |||
| TOTAL LIABILITIES AND EQUITY | 43.48B | 44.01B | 47.67B | 50.64B | 57.47B | |||
| Statistics | ||||||||
| Debt/Equity | 2.42 | 2.45 | 2.11 | 2.32 | 1.79 | |||
| Current Ratio | 1.02 | 1.05 | 1.14 | 0.99 | 0.98 | |||
| Return On Assets (ROA) | -1.29% | -5.56% | 0.87% | -7.88% | -1.74% | |||
| Return On Equity (ROE) | -7.45% | -31.34% | 4.06% | -39.80% | -7.15% | |||
| Return On Invested Capital (ROIC) | 8.95% | 7.73% | 7.37% | 6.59% | 4.90% | |||
| Return On Invested Capital Ex Cash (ROICexc) | 9.98% | 8.45% | 7.83% | 6.99% | 5.13% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 51.16% | 42.93% | 38.62% | 39.93% | 34.70% | |||
All data in USD